{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:20:03Z","timestamp":1793665203938,"version":"4.5.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T00:00:00Z","timestamp":1721520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T00:00:00Z","timestamp":1721520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL159900"],"award-info":[{"award-number":["R01HL159900"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL170260"],"award-info":[{"award-number":["R01HL170260"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21HL163720"],"award-info":[{"award-number":["R21HL163720"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL169976"],"award-info":[{"award-number":["R01HL169976"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Current gene therapy for Duchenne muscular dystrophy (DMD) utilizes adeno-associated virus (AAV) to deliver micro-dystrophin (\u00b5Dys), which does not provide full protection for striated muscles as it lacks many important functional domains of full-length (FL) dystrophin. Here we develop a triple vector system to deliver FL-dystrophin into skeletal and cardiac muscles. We split FL-dystrophin into three fragments linked to two orthogonal pairs of split intein, allowing efficient assembly of FL-dystrophin. The three fragments packaged in myotropic AAV (MyoAAV4A) restore FL-dystrophin expression in both skeletal and cardiac muscles in male\n                    <jats:italic>mdx<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>4cv<\/jats:italic>\n                    <\/jats:sup>\n                    mice. Dystrophin-glycoprotein complex components are also restored at the sarcolemma of dystrophic muscles. MyoAAV4A-delivered FL-dystrophin significantly improves muscle histopathology, contractility, and overall strength comparable to \u00b5Dys, but unlike \u00b5Dys, it also restores defective cavin 4 localization and associated signaling in\n                    <jats:italic>mdx<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>4cv<\/jats:italic>\n                    <\/jats:sup>\n                    heart. Therefore, our data support the feasibility of a mutation-independent FL-dystrophin gene therapy for DMD, warranting further clinical development.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-50569-6","type":"journal-article","created":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T02:04:01Z","timestamp":1721527441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9365-7460","authenticated-orcid":false,"given":"Yuan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4295-1536","authenticated-orcid":false,"given":"Weidong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7213-998X","authenticated-orcid":false,"given":"Roland W.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-9186","authenticated-orcid":false,"given":"Renzhi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,21]]},"reference":[{"key":"50569_CR1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt, E. et al. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur. J. Epidemiol. 35, 643\u2013653 (2020).","journal-title":"Eur. J. Epidemiol."},{"key":"50569_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0888-7543(88)90091-2","volume":"2","author":"S Forrest","year":"1988","unstructured":"Forrest, S. et al. Further studies of gene deletions that cause Duchenne and Becker muscular dystrophies. Genomics 2, 109\u2013114 (1988).","journal-title":"Genomics"},{"key":"50569_CR3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/0092-8674(91)90035-W","volume":"66","author":"JM Ervasti","year":"1991","unstructured":"Ervasti, J. M. & Campbell, K. P. Membrane organization of the dystrophin-glycoprotein complex. Cell 66, 1121\u20131131 (1991).","journal-title":"Cell"},{"key":"50569_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1083\/jcb.112.1.135","volume":"112","author":"K Ohlendieck","year":"1991","unstructured":"Ohlendieck, K., Ervasti, J. M., Snook, J. B. & Campbell, K. P. Dystrophin-glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma. J. Cell Biol. 112, 135\u2013148 (1991).","journal-title":"J. Cell Biol."},{"key":"50569_CR5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T","volume":"23","author":"RD Cohn","year":"2000","unstructured":"Cohn, R. D. & Campbell, K. P. Molecular basis of muscular dystrophies. Muscle Nerve 23, 1456\u20131471 (2000).","journal-title":"Muscle Nerve"},{"key":"50569_CR6","doi-asserted-by":"publisher","first-page":"12573","DOI":"10.1073\/pnas.0906545106","volume":"106","author":"R Han","year":"2009","unstructured":"Han, R. et al. Basal lamina strengthens cell membrane integrity via the laminin G domain-binding motif of alpha-dystroglycan. Proc. Natl Acad. Sci. USA 106, 12573\u201312579 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"50569_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07639-3","volume":"9","author":"JT Olthoff","year":"2018","unstructured":"Olthoff, J. T. et al. Loss of peroxiredoxin-2 exacerbates eccentric contraction-induced force loss in dystrophin-deficient muscle. Nat. Commun. 9, 5104 (2018).","journal-title":"Nat. Commun."},{"key":"50569_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00019052-200310000-00003","volume":"16","author":"F Muntoni","year":"2003","unstructured":"Muntoni, F. Cardiomyopathy in muscular dystrophies. Curr. Opin. Neurol. 16, 577\u2013583 (2003).","journal-title":"Curr. Opin. Neurol."},{"key":"50569_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.22097","volume":"44","author":"CF Spurney","year":"2011","unstructured":"Spurney, C. F. Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve 44, 8\u201319 (2011).","journal-title":"Muscle Nerve"},{"key":"50569_CR10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/d41573-023-00103-y","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard, A. FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections. Nat. Rev. Drug Discov. 22, 610 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"50569_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","volume":"343","author":"SB England","year":"1990","unstructured":"England, S. B. et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180\u2013182 (1990).","journal-title":"Nature"},{"key":"50569_CR12","doi-asserted-by":"publisher","first-page":"e1000958","DOI":"10.1371\/journal.pgen.1000958","volume":"6","author":"GB Banks","year":"2010","unstructured":"Banks, G. B., Judge, L. M., Allen, J. M. & Chamberlain, J. S. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 6, e1000958 (2010).","journal-title":"PLoS Genet."},{"key":"50569_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nm1439","volume":"12","author":"P Gregorevic","year":"2006","unstructured":"Gregorevic, P. et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12, 787\u2013789 (2006).","journal-title":"Nat. Med."},{"key":"50569_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","volume":"27","author":"JN Ramos","year":"2019","unstructured":"Ramos, J. N. et al. Development of novel micro-dystrophins with enhanced functionality. Mol. Ther. 27, 623\u2013635 (2019).","journal-title":"Mol. Ther."},{"key":"50569_CR15","doi-asserted-by":"publisher","first-page":"eabo1815","DOI":"10.1126\/scitranslmed.abo1815","volume":"15","author":"SM Birch","year":"2023","unstructured":"Birch, S. M. et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci. Transl. Med. 15, eabo1815 (2023).","journal-title":"Sci. Transl. Med."},{"key":"50569_CR16","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy, S. M. Delandistrogene moxeparvovec: first approval. Drugs 83, 1323\u20131329 (2023).","journal-title":"Drugs"},{"key":"50569_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nm0302-253","volume":"8","author":"SQ Harper","year":"2002","unstructured":"Harper, S. Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253\u2013261 (2002).","journal-title":"Nat. Med."},{"key":"50569_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.yjmcc.2012.05.002","volume":"53","author":"B Bostick","year":"2012","unstructured":"Bostick, B. et al. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy. J. Mol. Cell Cardiol. 53, 217\u2013222 (2012).","journal-title":"J. Mol. Cell Cardiol."},{"key":"50569_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/hum.2022.180","volume":"34","author":"LP Wasala","year":"2023","unstructured":"Wasala, L. P. et al. The implication of Hinge 1 and Hinge 4 in micro-dystrophin gene therapy for Duchenne muscular dystrophy. Hum. Gene Ther. 34, 459\u2013470 (2023).","journal-title":"Hum. Gene Ther."},{"key":"50569_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nbt0702-697","volume":"20","author":"CL Halbert","year":"2002","unstructured":"Halbert, C. L., Allen, J. M. & Miller, A. D. Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat. Biotechnol. 20, 697\u2013701 (2002).","journal-title":"Nat. Biotechnol."},{"key":"50569_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/mt.2010.205","volume":"19","author":"GL Odom","year":"2011","unstructured":"Odom, G. L., Gregorevic, P., Allen, J. M. & Chamberlain, J. S. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol. Ther. 19, 36\u201345 (2011).","journal-title":"Mol. Ther."},{"key":"50569_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/acn3.172","volume":"2","author":"PC Sondergaard","year":"2015","unstructured":"Sondergaard, P. C. et al. AAV.Dysferlin overlap vectors restore function in dysferlinopathy animal models. Ann. Clin. Transl. Neurol. 2, 256\u2013270 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"50569_CR23","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/mtm.2015.9","volume":"2","author":"M Pryadkina","year":"2015","unstructured":"Pryadkina, M. et al. A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb Dysferlin coding sequence. Mol. Ther. Methods Clin. Dev. 2, 15009 (2015).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"50569_CR24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/75080","volume":"6","author":"D Duan","year":"2000","unstructured":"Duan, D., Yue, Y., Yan, Z. & Engelhardt, J. F. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat. Med. 6, 595\u2013598 (2000).","journal-title":"Nat. Med."},{"key":"50569_CR25","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1073\/pnas.97.12.6716","volume":"97","author":"Z Yan","year":"2000","unstructured":"Yan, Z., Zhang, Y., Duan, D. & Engelhardt, J. F. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc. Natl Acad. Sci. USA 97, 6716\u20136721 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"50569_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.mt.6300322","volume":"16","author":"A Ghosh","year":"2008","unstructured":"Ghosh, A., Yue, Y., Lai, Y. & Duan, D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol. Ther. 16, 124\u2013130 (2008).","journal-title":"Mol. Ther."},{"key":"50569_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1089\/hum.2013.164","volume":"25","author":"T Koo","year":"2014","unstructured":"Koo, T., Popplewell, L., Athanasopoulos, T. & Dickson, G. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum. Gene Ther. 25, 98\u2013108 (2014).","journal-title":"Hum. Gene Ther."},{"key":"50569_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23996-y","volume":"12","author":"L Xu","year":"2021","unstructured":"Xu, L. et al. Efficient precise in vivo base editing in adult dystrophic mice. Nat. Commun. 12, 3719 (2021).","journal-title":"Nat. Commun."},{"key":"50569_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13578-023-01036-0","volume":"13","author":"Y Zuo","year":"2023","unstructured":"Zuo, Y. et al. Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice. Cell Biosci. 13, 109 (2023).","journal-title":"Cell Biosci."},{"key":"50569_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","volume":"4","author":"JM Levy","year":"2020","unstructured":"Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97\u2013110 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"50569_CR31","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","volume":"184","author":"M Tabebordbar","year":"2021","unstructured":"Tabebordbar, M. et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell 184, 4919\u20134938 e4922 (2021).","journal-title":"Cell"},{"key":"50569_CR32","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1021\/jacs.5b13528","volume":"138","author":"AJ Stevens","year":"2016","unstructured":"Stevens, A. J. et al. Design of a split intein with exceptional protein splicing activity. J. Am. Chem. Soc. 138, 2162\u20132165 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"50569_CR33","doi-asserted-by":"publisher","first-page":"28686","DOI":"10.1074\/jbc.M112.372680","volume":"287","author":"P Carvajal-Vallejos","year":"2012","unstructured":"Carvajal-Vallejos, P., Pallisse, R., Mootz, H. D. & Schmidt, S. R. Unprecedented rates and efficiencies revealed for new natural split inteins from metagenomic sources. J. Biol. Chem. 287, 28686\u201328696 (2012).","journal-title":"J. Biol. Chem."},{"key":"50569_CR34","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1128\/MCB.15.8.4086","volume":"15","author":"S Sadis","year":"1995","unstructured":"Sadis, S., Atienza, C. Jr. & Finley, D. Synthetic signals for ubiquitin-dependent proteolysis. Mol. Cell Biol. 15, 4086\u20134094 (1995).","journal-title":"Mol. Cell Biol."},{"key":"50569_CR35","doi-asserted-by":"crossref","unstructured":"Luo, L., Jea, J. D., Wang, Y., Chao, P. W. & Yen, L. Control of mammalian gene expression by modulation of polyA signal cleavage at 5\u2019 UTR. Nat. Biotechnol. (2024).","DOI":"10.1038\/s41587-023-01989-0"},{"key":"50569_CR36","doi-asserted-by":"publisher","first-page":"28792","DOI":"10.1074\/jbc.M115.677237","volume":"290","author":"AL Bachmann","year":"2015","unstructured":"Bachmann, A. L. & Mootz, H. D. An unprecedented combination of serine and cysteine nucleophiles in a split intein with an atypical split site. J. Biol. Chem. 290, 28792\u201328804 (2015).","journal-title":"J. Biol. Chem."},{"key":"50569_CR37","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/anie.201307969","volume":"53","author":"IV Thiel","year":"2014","unstructured":"Thiel, I. V., Volkmann, G., Pietrokovski, S. & Mootz, H. D. An atypical naturally split intein engineered for highly efficient protein labeling. Angew. Chem. 53, 1306\u20131310 (2014).","journal-title":"Angew. Chem."},{"key":"50569_CR38","doi-asserted-by":"publisher","first-page":"11791","DOI":"10.1021\/jacs.8b07334","volume":"140","author":"AJ Stevens","year":"2018","unstructured":"Stevens, A. J., Sekar, G., Gramespacher, J. A., Cowburn, D. & Muir, T. W. An atypical mechanism of split intein molecular recognition and folding. J. Am. Chem. Soc. 140, 11791\u201311799 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"50569_CR39","doi-asserted-by":"publisher","first-page":"12041","DOI":"10.1073\/pnas.2003613117","volume":"117","author":"AJ Burton","year":"2020","unstructured":"Burton, A. J., Haugbro, M., Parisi, E. & Muir, T. W. Live-cell protein engineering with an ultra-short split intein. Proc. Natl Acad. Sci. USA 117, 12041\u201312049 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"50569_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/6981","volume":"17","author":"X Li","year":"1999","unstructured":"Li, X., Eastman, E. M., Schwartz, R. J. & Draghia-Akli, R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol. 17, 241\u2013245 (1999).","journal-title":"Nat. Biotechnol."},{"key":"50569_CR41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ymthe.2022.11.012","volume":"31","author":"H Li","year":"2023","unstructured":"Li, H. et al. Systemic AAV9.BVES delivery ameliorates muscular dystrophy in a mouse model of LGMDR25. Mol. Ther. 31, 398\u2013408 (2023).","journal-title":"Mol. Ther."},{"key":"50569_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37496-8","volume":"14","author":"H Li","year":"2023","unstructured":"Li, H. et al. Defective BVES-mediated feedback control of cAMP in muscular dystrophy. Nat. Commun. 14, 1785 (2023).","journal-title":"Nat. Commun."},{"key":"50569_CR43","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/hmg\/ddab133","volume":"30","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Proteomic analysis identifies key differences in the cardiac interactomes of dystrophin and micro-dystrophin. Hum. Mol. Genet. 30, 1321\u20131336 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"50569_CR44","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1089\/hum.2008.009","volume":"19","author":"J Li","year":"2008","unstructured":"Li, J., Sun, W., Wang, B., Xiao, X. & Liu, X. Q. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum. Gene Ther. 19, 958\u2013964 (2008).","journal-title":"Hum. Gene Ther."},{"key":"50569_CR45","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1038\/sj.mt.6300268","volume":"15","author":"L Chen","year":"2007","unstructured":"Chen, L. et al. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol. Ther. 15, 1856\u20131862 (2007).","journal-title":"Mol. Ther."},{"key":"50569_CR46","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/hmg\/11.9.1095","volume":"11","author":"LE Warner","year":"2002","unstructured":"Warner, L. E. et al. Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Hum. Mol. Genet. 11, 1095\u20131105 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"50569_CR47","doi-asserted-by":"publisher","first-page":"294ra106","DOI":"10.1126\/scitranslmed.aaa4804","volume":"7","author":"MS Barnabei","year":"2015","unstructured":"Barnabei, M. S., Sjaastad, F. V., Townsend, D., Bedada, F. B. & Metzger, J. M. Severe dystrophic cardiomyopathy caused by the enteroviral protease 2A-mediated C-terminal dystrophin cleavage fragment. Sci. Transl. Med. 7, 294ra106 (2015).","journal-title":"Sci. Transl. Med."},{"key":"50569_CR48","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/pro.3357","volume":"27","author":"JA Gramespacher","year":"2018","unstructured":"Gramespacher, J. A., Stevens, A. J., Thompson, R. E. & Muir, T. W. Improved protein splicing using embedded split inteins. Protein Sci. 27, 614\u2013619 (2018).","journal-title":"Protein Sci."},{"key":"50569_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19230-w","volume":"11","author":"J Weinmann","year":"2020","unstructured":"Weinmann, J. et al. Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat. Commun. 11, 5432 (2020).","journal-title":"Nat. Commun."},{"key":"50569_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn4704","volume":"8","author":"J El Andari","year":"2022","unstructured":"El Andari, J. et al. Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders. Sci. Adv. 8, eabn4704 (2022).","journal-title":"Sci. Adv."},{"key":"50569_CR51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","volume":"12","author":"E Ruoslahti","year":"1996","unstructured":"Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697\u2013715 (1996).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"50569_CR52","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","volume":"388","author":"CG Bonnemann","year":"2023","unstructured":"Bonnemann, C. G. et al. Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 388, 2294\u20132296 (2023).","journal-title":"N. Engl. J. Med."},{"key":"50569_CR53","doi-asserted-by":"publisher","first-page":"e173510","DOI":"10.1172\/JCI173510","volume":"134","author":"SM Salabarria","year":"2024","unstructured":"Salabarria, S. M. et al. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J. Clin. Invest. 134, e173510 (2024).","journal-title":"J. Clin. Invest."},{"key":"50569_CR54","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ymthe.2024.03.016","volume":"32","author":"R Kaczmarek","year":"2024","unstructured":"Kaczmarek, R., Samelson-Jones, B. J. & Herzog, R. W. Immune tolerance induction by hepatic gene transfer: first-in-human evidence. Mol. Ther. 32, 863\u2013864 (2024).","journal-title":"Mol. Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50569-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T03:01:37Z","timestamp":1721530897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50569-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,21]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50569"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50569-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3867299\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,21]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Indiana University has filed a provisional patent application (inventor: R.H.) based on the work reported in this paper. R.H. is a founder of Zhida Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6141"}}